about
Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993-2002.Trends in sources of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia: data from the national mandatory surveillance of MRSA bacteraemia in England, 2006-2009.Group B streptococcal disease in UK and Irish infants younger than 90 days.Epidemiology of severe Streptococcus pyogenes disease in Europe.Candida parapsilosis infection in very low birthweight infants.Invasive group a streptococcal disease: epidemiology, pathogenesis and management.Control measures for invasive group A streptococci (iGAS) outbreaks in care homes.Increase in scarlet fever notifications in the United Kingdom, 2013/2014.Group B streptococcal disease in infants: a case control study.The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009.Risk factors for surgical site infection following caesarean section in England: results from a multicentre cohort study.Improving patient safety through surgical site infection surveillance: response to Tanner et al.Unexplained increase in Paecilomyces variotii blood culture isolates in the UK.Characterization of group B streptococci recovered from infants with invasive disease in England and Wales.A methodological approach to investigating a nationwide clinical specimen contamination problem in England.Infection-related mortality in children with malignancy in England and Wales, 2003-2005.Risk factors for surgical site infection following caesarean section in England. Authors' reply.Failure to vaccinate current injecting drug users against hepatitis B in England and Wales.Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996.The HIV epidemic in injecting drug users.Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004.Increasing incidence of group A streptococcal infections amongst injecting drug users in England and Wales.Continuing impact of infectious diseases on childhood deaths in England and Wales, 2003-2005.Risk factors for fatality in Panton-Valentine leukocidin-producing Staphylococcus aureus pneumonia cases, England, 2012-2013.THE CONTRIBUTION OF INFECTIONS TO NEONATAL DEATHS IN ENGLAND AND WALESMortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004–2005Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011Predictors of Death after SevereStreptococcus pyogenesInfectionGuidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UKNew cases seen at genitourinary medicine clinics: England 1998The national CD4 surveillance scheme for England and WalesThe potential for a concerted system for the rapid monitoring of excess mortality throughout EuropeStreptococcus pyogenes cluster in a care home in England April to June 2010Increase in invasive group A streptococcal infections in England, Wales and Northern Ireland, 2008-9Effect of ribotype on all-cause mortality following Clostridium difficile infection
P50
Q30979105-F61837AE-0C29-48E5-9B52-057B3E913127Q33963159-7855FFBC-0E74-488F-A37E-E46AE6C28721Q34293655-5ADFBB08-5638-4FEE-87A0-1EE282D7B54EQ36747672-A70ADBB9-02A5-4A34-8746-C6F8DF87192AQ37174924-E1C14540-81DE-432B-9A61-8CBB3C181996Q38017734-2A508EA1-2081-4B56-BC60-9BBEA7343D5CQ39679871-D8CB0C62-47D1-4751-BA61-E192C871C261Q40211757-CEABA195-0C8E-44C9-AC5C-E512EDEF0516Q40389142-C06D8573-0F15-4F2C-9B9B-F2849F183B06Q42282576-76FE4282-24B0-47E3-89C5-78164D4D2AB6Q43668245-6E02D857-570C-4BCF-A713-550585F63504Q43860423-DA871516-17DC-4330-ABA6-D18C61A595AAQ44190018-027407EA-21DF-4E82-9CED-8BDC53ACD35AQ44341151-CA9EC2C3-64BC-486C-8960-1B37599B8A4EQ45922948-315CA730-885A-4E67-B7A9-C4386BE05455Q46310028-81528757-7905-41B7-A046-F2F79A7C2BB8Q46415435-4B42A879-FE58-4D87-A532-CEAA831E78CCQ47575395-19E52369-84F9-4230-A680-EE3290D643CDQ47599197-2E4F1F94-3B82-4155-A9EE-558BA9113D5FQ47619692-E96ABB39-8DBB-4BB1-BC31-4EA6B86A760EQ47650707-3842EB64-0DE1-4114-901B-86D8E301F7B9Q47911788-810EA783-DB48-436E-9917-BCFC3ECBACBBQ53177512-06D8E0BD-C5D1-4B51-8246-4B4B8F200761Q53290911-DFBAF9AF-01D2-4E6F-9E41-F130D467DD9BQ57385741-75087CA2-7A70-482A-9BC9-2D2F955BCD70Q57385743-25F8E8A8-C506-4A8E-86AD-1ED401AFA2B3Q57385746-5C48B8D5-677E-40F2-BB3A-2A51570F25B5Q57385752-98D21C5D-9230-4674-953B-1E19EAB6E5C0Q63859514-919490A5-85DB-4E4C-9BD0-B55D103C7C61Q73354532-6D2B61CB-B873-4031-8971-381BA45B110FQ74246510-E74558CF-93F6-4FC1-BFC7-6078A34D8DEFQ82504929-7AA1A1F3-09C0-4011-A8C8-A017B3805503Q82864096-ED2211DB-0CF3-4632-A2B3-CD6E18E9FE55Q83345657-73E496F9-C018-47D5-941A-C33766B1F84BQ86939756-50C80840-9877-4DCA-B2A9-B1CD72E51B2D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Theresa L Lamagni
@ast
Theresa L Lamagni
@en
Theresa L Lamagni
@es
Theresa L Lamagni
@nl
Theresa L Lamagni
@sl
type
label
Theresa L Lamagni
@ast
Theresa L Lamagni
@en
Theresa L Lamagni
@es
Theresa L Lamagni
@nl
Theresa L Lamagni
@sl
prefLabel
Theresa L Lamagni
@ast
Theresa L Lamagni
@en
Theresa L Lamagni
@es
Theresa L Lamagni
@nl
Theresa L Lamagni
@sl
P106
P21
P31
P496
0000-0002-3965-8323